RECRUITING

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Talk to us

Conditions

Transthyretin-Mediated AmyloidosisATTR AmyloidosisRNAi therapeuticTransthyretinTTRAmyloidosisHereditary Transthyretin-mediated (hATTR) AmyloidosishATTR amyloidosisHereditary ATTR amyloidosisWild-type amyloidosiswtATTR amyloidosisATTRv amyloidosisATTRwt amyloidosisPolyneuropathyFamilial amyloid polyneuropathiesATTRTransthyretin amyloidosisTTR-mediated amyloidosisPolyneuropathiesAmyloid neuropathiesAmyloid neuropathies, familialAmyloidosis, familial

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant

Official Title

ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Quick Facts

Study Start:2020-11-23
Study Completion:2030-09-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04561518

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers
  2. * Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis
  1. * Current enrollment in a clinical trial for any investigational agent

Contacts and Locations

Study Contact

Alnylam Clinical Trial Information Line
CONTACT
1-877-ALNYLAM
clinicaltrials@alnylam.com
Alnylam Clinical Trial Information Line
CONTACT
1-877-256-9526
clinicaltrials@alnylam.com

Principal Investigator

Medical Director
STUDY_DIRECTOR
Alnylam Pharmaceuticals

Study Locations (Sites)

Clinical Trial Site
La Jolla, California, 92037
United States
Clinical Trial Site
Los Angeles, California, 90095
United States
Clinical Trial Site
Jacksonville, Florida, 32224
United States
Clinical Trial Site
Iowa City, Iowa, 52242
United States
Clinical Trial Site
Kansas City, Kansas, 66160
United States
Clinical Trial Site
Baltimore, Maryland, 21224
United States
Clinical Trial Site
Boston, Massachusetts, 02127
United States
Clinical Trial Site
New York, New York, 10034
United States
Clinical Trial Site
Durham, North Carolina, 27710
United States
Clinical Trial Site
Columbus, Ohio, 43210
United States
Clinical Trial Site
Philadelphia, Pennsylvania, 19104
United States
Clinical Trial Site
Austin, Texas, 78756
United States
Clinical Trial Site
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: Alnylam Pharmaceuticals

  • Medical Director, STUDY_DIRECTOR, Alnylam Pharmaceuticals

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-11-23
Study Completion Date2030-09-01

Study Record Updates

Study Start Date2020-11-23
Study Completion Date2030-09-01

Terms related to this study

Keywords Provided by Researchers

  • RNAi therapeutic
  • Transthyretin
  • TTR
  • Amyloidosis
  • Hereditary Transthyretin-mediated (hATTR) Amyloidosis
  • hATTR amyloidosis
  • Hereditary ATTR amyloidosis
  • Wild-type amyloidosis
  • wtATTR amyloidosis
  • ATTRv amyloidosis
  • ATTRwt amyloidosis
  • Polyneuropathy
  • Familial amyloid polyneuropathies
  • ATTR
  • Transthyretin amyloidosis
  • TTR-mediated amyloidosis
  • Polyneuropathies
  • Amyloid neuropathies
  • Amyloid neuropathies, familial
  • Amyloidosis, familial

Additional Relevant MeSH Terms

  • Transthyretin-Mediated Amyloidosis
  • ATTR Amyloidosis